ATE323697T1 - Neue benzo-1,3-dioxolyl-und benzofuranyl substituierte pyrrolidinederivate als endothelin antagonisten - Google Patents
Neue benzo-1,3-dioxolyl-und benzofuranyl substituierte pyrrolidinederivate als endothelin antagonistenInfo
- Publication number
- ATE323697T1 ATE323697T1 AT97905816T AT97905816T ATE323697T1 AT E323697 T1 ATE323697 T1 AT E323697T1 AT 97905816 T AT97905816 T AT 97905816T AT 97905816 T AT97905816 T AT 97905816T AT E323697 T1 ATE323697 T1 AT E323697T1
- Authority
- AT
- Austria
- Prior art keywords
- dioxolyl
- endothelin antagonists
- pyrrolidine derivatives
- substituted pyrrolidine
- new benzo
- Prior art date
Links
- -1 BENZO-1,3-DIOXOLYL Chemical group 0.000 title 2
- 102000002045 Endothelin Human genes 0.000 title 1
- 108050009340 Endothelin Proteins 0.000 title 1
- RWRDLPDLKQPQOW-UHFFFAOYSA-N Pyrrolidine Chemical class C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 title 1
- 239000005557 antagonist Substances 0.000 title 1
- ZUBDGKVDJUIMQQ-UBFCDGJISA-N endothelin-1 Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(O)=O)NC(=O)[C@H]1NC(=O)[C@H](CC=2C=CC=CC=2)NC(=O)[C@@H](CC=2C=CC(O)=CC=2)NC(=O)[C@H](C(C)C)NC(=O)[C@H]2CSSC[C@@H](C(N[C@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@H](CC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(O)=O)C(=O)N2)=O)NC(=O)[C@@H](CO)NC(=O)[C@H](N)CSSC1)C1=CNC=N1 ZUBDGKVDJUIMQQ-UBFCDGJISA-N 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D207/16—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pulmonology (AREA)
- Urology & Nephrology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Vascular Medicine (AREA)
- Hospice & Palliative Care (AREA)
- Diabetes (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Hematology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Pyrrole Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US60062596A | 1996-02-13 | 1996-02-13 | |
| US79450697A | 1997-02-04 | 1997-02-04 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE323697T1 true ATE323697T1 (de) | 2006-05-15 |
Family
ID=27083659
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT97905816T ATE323697T1 (de) | 1996-02-13 | 1997-02-12 | Neue benzo-1,3-dioxolyl-und benzofuranyl substituierte pyrrolidinederivate als endothelin antagonisten |
Country Status (17)
| Country | Link |
|---|---|
| EP (2) | EP1609790A3 (de) |
| JP (1) | JP2002504081A (de) |
| KR (1) | KR100508200B1 (de) |
| CN (2) | CN1091768C (de) |
| AR (1) | AR006309A1 (de) |
| AT (1) | ATE323697T1 (de) |
| AU (1) | AU2262097A (de) |
| BR (1) | BR9707509A (de) |
| CA (2) | CA2245587C (de) |
| CZ (1) | CZ296660B6 (de) |
| DE (1) | DE69735710T2 (de) |
| DK (1) | DK0885215T3 (de) |
| ES (1) | ES2259803T3 (de) |
| IL (2) | IL125177A0 (de) |
| NZ (1) | NZ330818A (de) |
| PT (1) | PT885215E (de) |
| WO (1) | WO1997030045A1 (de) |
Families Citing this family (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7208517B1 (en) | 1994-08-19 | 2007-04-24 | Abbott Labortories | Endothelin antagonists |
| DE19743681A1 (de) * | 1997-10-02 | 1999-04-08 | Knoll Ag | Methode zur Verhinderung der Transplantatabstoßung |
| US6410554B1 (en) | 1998-03-23 | 2002-06-25 | Merck & Co., Inc. | Combination therapy for the treatment of benign prostatic hyperplasia |
| AU755530B2 (en) * | 1998-07-15 | 2002-12-12 | Bristol-Myers Squibb Company | Stereoselective reductive amination of ketones |
| EP1114022A1 (de) * | 1998-09-14 | 2001-07-11 | Abbott Laboratories | Verfahren zur herstellung von stereoselektiven nitro-verbindungen |
| TWI306760B (en) * | 2000-08-07 | 2009-03-01 | Abbott Lab | Use of an endothelin et-a receptor antagonist and orally delivered pharmaceutical composition comprising the same |
| WO2002017912A1 (en) * | 2000-08-31 | 2002-03-07 | Abbott Laboratories | Endothelin antagonists |
| WO2004005262A2 (en) | 2002-07-02 | 2004-01-15 | Schering Corporation | New neuropeptide y y5 receptor antagonists |
| FR2874015B1 (fr) * | 2004-08-05 | 2006-09-15 | Sanofi Synthelabo | Derives de n-(1h-indolyl)-1h-indole-2-carboxamides, leur preparation et leur application en therapeutique |
| FR2880625B1 (fr) * | 2005-01-07 | 2007-03-09 | Sanofi Aventis Sa | Derives de n-(heteroaryl)-1h-indole-2-carboxamides, leur preparation et leur application en therapeutique |
| EP2190433A2 (de) | 2007-08-22 | 2010-06-02 | Gilead Colorado, Inc. | Therapie für diabeteskomplikationen |
| ATE506359T1 (de) * | 2007-11-30 | 2011-05-15 | Bayer Schering Pharma Ag | Heteroaryl-substituierte piperidine |
| WO2011114103A1 (en) | 2010-03-18 | 2011-09-22 | Biolipox Ab | Pyrimidinones for use as medicaments |
| JO2998B1 (ar) | 2010-06-04 | 2016-09-05 | Amgen Inc | مشتقات بيبيريدينون كمثبطات mdm2 لعلاج السرطان |
| WO2013049250A1 (en) | 2011-09-27 | 2013-04-04 | Amgen Inc. | Heterocyclic compounds as mdm2 inhibitors for the treatment of cancer |
| US11407721B2 (en) | 2013-02-19 | 2022-08-09 | Amgen Inc. | CIS-morpholinone and other compounds as MDM2 inhibitors for the treatment of cancer |
| CN105121407B (zh) | 2013-02-28 | 2017-07-18 | 美国安进公司 | 用于治疗癌症的苯甲酸衍生物mdm2抑制剂 |
| MX374513B (es) | 2013-03-14 | 2025-03-06 | Amgen Inc | Compuestos de morfolinona de ácido heteroarilo como inhibidores mdm2 para el tratamiento de cáncer. |
| JOP20200296A1 (ar) | 2013-06-10 | 2017-06-16 | Amgen Inc | عمليات صنع وأشكال بلورية من mdm2 مثبط |
| CN109400567A (zh) * | 2018-12-05 | 2019-03-01 | 华中药业股份有限公司 | 一种合成甘草素的方法 |
| KR20230015874A (ko) | 2019-12-17 | 2023-01-31 | 치누크 세라퓨틱스, 인크. | 아트라센탄에 의해 iga 신장병증을 치료하는 방법 |
| CN118772120A (zh) * | 2021-09-03 | 2024-10-15 | 深圳信立泰药业股份有限公司 | 一种内皮素a(eta)受体拮抗剂化合物及其制备方法和医药用途 |
| CN119487020B (zh) * | 2022-07-25 | 2025-10-03 | 深圳信立泰药业股份有限公司 | 一种内皮素a(eta)受体拮抗剂化合物的盐及其制备方法和医药用途 |
| CN117447453B (zh) * | 2022-07-25 | 2025-09-30 | 深圳信立泰药业股份有限公司 | 一种内皮素a(eta)受体拮抗剂化合物可药用的盐晶型及其制备方法 |
| CN120302971A (zh) | 2022-10-28 | 2025-07-11 | 奇努克治疗公司 | 使用内皮素受体拮抗剂和april结合抗体治疗iga肾病 |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK0612244T3 (da) * | 1991-11-05 | 2002-01-14 | Smithkline Beecham Corp | Endothelinreceptorantagonister |
| EP0650484B1 (de) * | 1992-07-17 | 2000-01-26 | Smithkline Beecham Corporation | Endothelin rezeptor antagonisten |
| ATE219077T1 (de) * | 1994-08-19 | 2002-06-15 | Abbott Lab | Endothelin antagoniste |
-
1997
- 1997-02-12 AT AT97905816T patent/ATE323697T1/de not_active IP Right Cessation
- 1997-02-12 JP JP52939797A patent/JP2002504081A/ja active Pending
- 1997-02-12 CA CA002245587A patent/CA2245587C/en not_active Expired - Fee Related
- 1997-02-12 DK DK97905816T patent/DK0885215T3/da active
- 1997-02-12 CN CN97192184A patent/CN1091768C/zh not_active Expired - Lifetime
- 1997-02-12 IL IL12517797A patent/IL125177A0/xx active IP Right Grant
- 1997-02-12 KR KR10-1998-0706247A patent/KR100508200B1/ko not_active Expired - Fee Related
- 1997-02-12 NZ NZ330818A patent/NZ330818A/xx not_active IP Right Cessation
- 1997-02-12 DE DE69735710T patent/DE69735710T2/de not_active Expired - Lifetime
- 1997-02-12 WO PCT/US1997/001936 patent/WO1997030045A1/en not_active Ceased
- 1997-02-12 PT PT97905816T patent/PT885215E/pt unknown
- 1997-02-12 CZ CZ0253798A patent/CZ296660B6/cs not_active IP Right Cessation
- 1997-02-12 AR ARP970100553A patent/AR006309A1/es unknown
- 1997-02-12 ES ES97905816T patent/ES2259803T3/es not_active Expired - Lifetime
- 1997-02-12 EP EP05106190A patent/EP1609790A3/de not_active Withdrawn
- 1997-02-12 EP EP97905816A patent/EP0885215B1/de not_active Expired - Lifetime
- 1997-02-12 BR BR9707509A patent/BR9707509A/pt not_active IP Right Cessation
- 1997-02-12 AU AU22620/97A patent/AU2262097A/en not_active Abandoned
- 1997-02-12 CA CA002634973A patent/CA2634973A1/en not_active Abandoned
-
1998
- 1998-07-01 IL IL125177A patent/IL125177A/en not_active IP Right Cessation
-
2002
- 2002-02-09 CN CN02104623A patent/CN1384100A/zh active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| CN1384100A (zh) | 2002-12-11 |
| JP2002504081A (ja) | 2002-02-05 |
| CZ296660B6 (cs) | 2006-05-17 |
| EP0885215B1 (de) | 2006-04-19 |
| WO1997030045A1 (en) | 1997-08-21 |
| PT885215E (pt) | 2006-08-31 |
| EP0885215A1 (de) | 1998-12-23 |
| IL125177A0 (en) | 1999-03-12 |
| KR19990082514A (ko) | 1999-11-25 |
| CA2634973A1 (en) | 1997-08-21 |
| KR100508200B1 (ko) | 2005-12-16 |
| NZ330818A (en) | 2000-05-26 |
| AU2262097A (en) | 1997-09-02 |
| BR9707509A (pt) | 1999-07-27 |
| CA2245587A1 (en) | 1997-08-21 |
| DK0885215T3 (da) | 2006-08-14 |
| DE69735710T2 (de) | 2007-03-29 |
| AR006309A1 (es) | 1999-08-25 |
| IL125177A (en) | 2007-12-03 |
| DE69735710D1 (de) | 2006-05-24 |
| CA2245587C (en) | 2008-12-30 |
| CN1091768C (zh) | 2002-10-02 |
| CZ253798A3 (cs) | 1999-07-14 |
| EP1609790A3 (de) | 2006-01-04 |
| CN1219172A (zh) | 1999-06-09 |
| EP1609790A2 (de) | 2005-12-28 |
| ES2259803T3 (es) | 2006-10-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ATE323697T1 (de) | Neue benzo-1,3-dioxolyl-und benzofuranyl substituierte pyrrolidinederivate als endothelin antagonisten | |
| ATE233260T1 (de) | Muscarin-antagonisten | |
| DK0846668T3 (da) | Vandafvisende sammensætning | |
| DE69607178D1 (de) | Mikroemulsionsförmige Desinfektionszusammensetzung | |
| ATE323079T1 (de) | Neue sulfamiden und deren verwendung als endothelin-antagonisten | |
| DK1167392T3 (da) | Materialer til anvendelse i papirfremstilling | |
| ID15991A (id) | Pengontrol serangga | |
| NO985293L (no) | Nye 2,3-disubstituerte-4(3H)-kinazolinoner | |
| DE69724557D1 (de) | Dokumentenanalyse | |
| DE69708071D1 (de) | Sicherheitsdokument | |
| DE69818248D1 (de) | Chinolin- und chinazolin-derivate als crf antagonisten | |
| ATE184015T1 (de) | Neue 19-nor-pregnen-derivate | |
| DE69626220D1 (de) | 3-azetidinylalkylpiperidine oder -pyrrolidine als tachykinin antagonisten | |
| DE69714265D1 (de) | Tetrahydrochinolinderivate als eaa antagonisten | |
| DE69729366D1 (de) | Wasserabstossende Zusammensetzung | |
| DE69718786D1 (de) | Benzoxazinone als dopamine -d4- rezeptor-antagonisten | |
| DE59813430D1 (de) | Perylenhydrazidimide als Carbonylderivatisierungsreagenzien | |
| ATE220294T1 (de) | Arthropodenrepellents | |
| DE69735811D1 (de) | Piperazinoderivate als neurokinin-antagonisten | |
| BR9702241A (pt) | Composição aquosa | |
| ATE220673T1 (de) | 4-(benzo-1,3-dioxolyl)-pyrrolidin-3-carbonsaure derivate als endothelin-antagonisten | |
| FI974518A0 (fi) | Sugvalsarrangemang foer pressen i en cellulosatorkmaskin | |
| DE69715223D1 (de) | Heteroaryloxyethylaminen als 5-ht1a rezeptor liganden | |
| DE59705484D1 (de) | Hubverstelleinrichtung | |
| NO983505L (no) | Nye fenantridiner |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| UEP | Publication of translation of european patent specification |
Ref document number: 0885215 Country of ref document: EP |
|
| REN | Ceased due to non-payment of the annual fee |